A REVOLUTIONARY DRUG: RITLECITINIB 【IF: 0】FOUNDRY JOURNAL. 2023 Sep Ritlecitinib purchased from AbMole
Patent. LU502505B1 【IF: 0】Patent. LU502505B1 2023 Jan 16 Cell Counting Kit-8 purchased from AbMole
Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders 【IF: 0】Patent: US20230218577A1 2023 Jul CUDC-305 purchased from AbMole
Patent. CA3158870A1 【IF: 0】Patent. CA3158870A1 2023 Nov 12 Panitumumab purchased from AbMole
Patent. CN115558633A 【IF: 0】Patent. CN115558633A 2023 Jan 03 Y-27632 dihydrochloride purchased from AbMole
Patent. US2023364025A1 【IF: 0】Patent. US2023364025A1 2023 Nov 16 Panitumumab purchased from AbMole
Patent. CN117074141A 【IF: 0】Patent. CN117074141A 2023 Nov 17 Y-27632 dihydrochloride purchased from AbMole
Patent. CN115671142A 【IF: 0】Patent. CN115671142A 2023 Feb 03 Y-27632 dihydrochloride purchased from AbMole
Progesterone is an Inducement of Heritable Pulmonary Arterial Hypertension with BMPR2 Mutation 【IF: 0】bioRxiv. 2023 Jun Mifepristone purchased from AbMole
Patent. CN112779209B 【IF: 0】Patent. CN112779209B 2023 Jan 24 Y-27632 dihydrochloride purchased from AbMole
Patent. CN117025537A 【IF: 0】Patent. CN117025537A 2023 Nov 10 FLI-06 purchased from AbMole
Patent. CN115869340A 【IF: 0】Patent. CN115869340A 2023 Mar 31 Temozolomide purchased from AbMole
Products are for research use only. Not for human use. We do not sell to patients.© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
